The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: A 24-week continuation therapy

Psychiatry and Clinical Neurosciences

Volumn 59, Issue 6, 2005, Pages 743-747

  Kim, Won ^a   Pae, Chi Un ^b   Chae, Jeong Ho ^b   Jun, Tae Youn ^b   Bahk, Won Myong ^a,b  

^a Inje University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Continuation treatment; Mirtazapine; Pharmacotherapy; Post traumatic stress disorder

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; MIRTAZAPINE; MOOD STABILIZER; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IMPACT OF EVENTS SCALE; LONG TERM CARE; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; POSTTRAUMATIC STRESS DISORDER; SHORT COURSE THERAPY; SIDE EFFECT; STRUCTURED INTERVIEW; WEIGHT GAIN;

EID: 31444450770     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2005.01447.x     Document Type: Article

References (28)

1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry 1995; 52: 1048-1060.
2. Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J. Consult. Clin. Psychol. 1993; 61: 984-991.
3. Breslau N, Davis GC. Posttraumatic stress disorder in an urban population of young adults: risk factors for chronicity. Am. J. Psychiatry 1992; 149: 671-675.
4. Marshall RD, Olfson M, Hellman F, Blanco C, Guardino M, Struening EL. Comorbidity, impairment, and suicidality in subthreshold PTSD. Am. J. Psychiatry 2001; 158: 1467-1473.
5. Davidson JR, Connor KM. Management of post-traumatic stress disorder: diagnostic and therapeutic issues. J. Clin. Psychiatry 1999; 60: 33-38.
6. Brady K, Pearlstein T, Asnis GM et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283: 1837-1844.
7. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry 2001; 58: 485-492.
8. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 2001; 158: 1982-1988.
9. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in posttraumatic stress disorder: randomized, double-blind study. Br. J. Psychiatry 1999; 175: 17-22.
10. Escalona R, Canive JM, Calais LA, Davidson JR. Fluvoxamine treatment in veterans with combat-related posttraumatic stress disorder. Depress. Anxiety 2002; 15: 29-33.
11. Foster PL, Schoenfeld FB, Marmar CR, Lang AJ. Lithium for irritability in post-traumatic stress disorder. J. Trauma Stress 1995; 8: 143-149.
12. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J. Clin. Psychiatry 1991; 52: 361-364.
13. Wolf ME, Alavi A, Mosnaim AD. Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings: possible therapeutic effects of carbamazepine. Biol. Psychiatry 1988; 23: 642-644.
14. Hertzberg MA, Butterfield MI, Feldman ME et al. A preliminary study of lamotrigine for the treatment of posttarumatic stress disorder. Biol Psychiatry 1999; 45: 1226-1229.
15. Harmon RJ, Riggs PD. Clonidine for posttraumatic stress disorder in preschool children. J. Am. Acad. Child Adolesc. Psychiatry 1996; 35: 1247-1249.
16. Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood, acute type. A pilot study. Am. J. Dis. Child. 1988; 142: 1244-1247.
17. Connor KM, Davidson JR, Weisler RH, Ahearn E. A pilot study of mirtazapine in posttraumatic stress disorder. Int. Clin. Psychopharmacol. 1999; 14: 29-31.
18. Davidson JR, Weisler RH, Butterfield MI et al. Mirtazapine vs placebo in posttraumatic stress disorder: a pilot trial. Biol. Psychiatry 2003; 53: 188-191.
19. Bahk WM, Pae CU, Tsoh J et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum. Psychopharmacol. 2002; 17: 341-344.
20. Davidson JR, Malik MA, Travers J. Structured interview for PTSD (SIP): psychometric validation for DSM-IV criteria. Depress. Anxiety 1997; 5: 127-129.
21. Connor KM, Davidson JR. SPRINT: a brief global assessment of post-traumatic stress disorder. Int. Clin. Psychopharmacol. 2001;16: 279-284.
22. Weiss DS, Marmar CR. The impact of event scale-revised. In: Wilson JP, Keane TM (eds). Assessing Psychological Trauma and PTSD. Guilford, New York, 1996; 399-411.
23. Montgomery SA, Âsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979; 134: 382-389.
24. Cyr M, Farrar MK. Treatment for posttraumatic stress disorder. Ann. Pharmacother. 2000; 34: 366-376.
25. Feldman TB. Alprazolam in the treatment of posttraumtaic stress disorder. J. Clin. Psychiatry 1987; 48: 216-217.
26. Keller MB, Boland RJ. Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol. Psychiatry 1998; 44: 348-360.
27. Montgomery SA, Kasper S. Depression: a long-term illness and its treatment. Int. Clin. Psychopharmacol. 1998; 13: S23-S26.
28. Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsive disorder. Depress. Anxiety 1998; 8: S105-S113.